BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12603585)

  • 41. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer.
    Wein A; Riedel C; Brückl W; Kastl S; Reingruber B; Hohenberger W; Hahn EG
    Z Gastroenterol; 2001 Feb; 39(2):153-6. PubMed ID: 11253506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Adjuvant systemic chemo- or immunotherapy of colon cancer].
    Schlag PM
    Chirurg; 1994 Jun; 65(6):503-8. PubMed ID: 8088205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma.
    Scheithauer W; Kornek G; Rosen H; Sebesta C; Marcell A; Kwasny W; Karall M; Depisch D
    Eur J Cancer; 1995 Nov; 31A(12):1981-6. PubMed ID: 8562152
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The tea leaves of small trials.
    Harrington DP
    J Clin Oncol; 1999 May; 17(5):1336-8. PubMed ID: 10334516
    [No Abstract]   [Full Text] [Related]  

  • 46. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
    Monz BU; König HH; Leidl R; Staib L; Link KH
    Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of 5-fluorouracil adjuvant treatment of colon cancer.
    Kelder W; Hospers GA; Plukker JT
    Expert Rev Anticancer Ther; 2006 May; 6(5):785-94. PubMed ID: 16759168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
    Medinger M; Steinbild S; Mross K
    Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin.
    Dencausse Y; Hartung G; Sturm J; Kopp-Schneider A; Hagmüller E; Wojatschek C; Lindemann H; Fritze D; Queisser W
    Onkologie; 2002 Oct; 25(5):426-30. PubMed ID: 12415196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
    Moertel CG; Fleming TR; Macdonald JS; Haller DG; Laurie JA; Tangen CM; Ungerleider JS; Emerson WA; Tormey DC; Glick JH
    J Clin Oncol; 1995 Dec; 13(12):2936-43. PubMed ID: 8523058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal.
    Sobrero A
    Lancet Oncol; 2006 Jun; 7(6):515-6. PubMed ID: 16750502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Colonic cancer. Adjuvant therapy: the Italian experience].
    Cascinu S; Salvagni S; Camisa R; Gasparro D; Biscari L; Pucci F; Leonardi F; Franciosi V
    Tumori; 2001; 87(1 Suppl 1):S83-4. PubMed ID: 11300038
    [No Abstract]   [Full Text] [Related]  

  • 53. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase I study of 5-fluorouracil, leucovorin and levamisole.
    Cleary JF; Arzoomanian R; Alberti D; Feierabend C; Storer B; Witt P; Carbone P; Wilding G
    Cancer Chemother Pharmacol; 1997; 39(4):300-6. PubMed ID: 9025770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ
    J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
    Wolmark N; Rockette H; Mamounas E; Jones J; Wieand S; Wickerham DL; Bear HD; Atkins JN; Dimitrov NV; Glass AG; Fisher ER; Fisher B
    J Clin Oncol; 1999 Nov; 17(11):3553-9. PubMed ID: 10550154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal.
    Köhne CH
    Lancet Oncol; 2006 Jun; 7(6):516-7. PubMed ID: 16767832
    [No Abstract]   [Full Text] [Related]  

  • 58. Fluorouracil and folinic acid in colon cancer. IMPACT Investigators.
    Marsoni S
    Lancet; 1995 Jun; 345(8964):1582-3. PubMed ID: 7791476
    [No Abstract]   [Full Text] [Related]  

  • 59. Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer.
    Ahn JB; Shim KY; Jeung HC; Rha SY; Yoo NC; Kim NK; Roh JK; Min JS; Kim BS; Chung HC
    Cancer Lett; 2001 Jun; 167(2):215-24. PubMed ID: 11369143
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.